|
|
Volumn 28, Issue 1, 1999, Pages 49-51
|
|
Editorial response: U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPHOTERICIN B CHOLESTEROL SULFATE;
AMPHOTERICIN B LIPID COMPLEX;
MEGLUMINE ANTIMONATE;
STIBOGLUCONATE SODIUM;
AMPHOTERICIN B;
ANTIPROTOZOAL AGENT;
DRUG CARRIER;
LIPOSOME;
DRUG APPROVAL;
DRUG CHOICE;
DRUG EFFICACY;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOCOMPETENCE;
PRIORITY JOURNAL;
VISCERAL LEISHMANIASIS;
CLINICAL TRIAL;
NOTE;
UNITED STATES;
AMPHOTERICIN B;
ANTIPROTOZOAL AGENTS;
CLINICAL TRIALS;
DRUG APPROVAL;
DRUG CARRIERS;
HUMANS;
LEISHMANIASIS, VISCERAL;
LIPOSOMES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0032618649
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/515086 Document Type: Editorial |
|
Times cited : (64)
|
|
References (11)
|
